Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Yentreve opvejede risiciene ved behandling af moderat til svær stressinkontinens.
The Committee for Medicinal Products for Human Use (CHMP) decided that Yentreve’ s benefits are greater than its risks for the treatment of moderate to severe SUI.